David Palmer thinks ClearCount Medical Solutions’ technology will push it over the top in the burgeoning surgical-sponge-detection market.ClearCount, which uses embedded radio-frequency ID chips to track and detect sponges, has the backing of Draper Triangle Ventures as it wrestles with two major competitors for control of the market. After raising $3.4 million last year in [...]

Respiratory-assistance company ALung Technologies Inc. has added $2.8 million in equity to what it hopes will be a $10 million round of investment funding, according to a Securities and Exchange Commission filing.The latest fundraise brings to $6.1 million the amount that ALung has raised since February. The funding includes contributions from 22 investors, according to [...]

ThermalTherapeutic Systems Inc. has received clearance from the U.S. Food and Drug Administration to begin selling its flagship portable perfusion device, which is used to pump fluid into the abdomen or chest cavity of patients suffering from hyperthermia.Obtaining FDA clearance of the Veratherm Portable Hyperthermic Perfusion System is a “critical step,” for the company, which [...]

Lipella Pharmaceuticals has big plans for the rest of the year, including raising its first venture funding and completing clinical trials for its drug that treats two common bladder conditions.

Cohera’s lead product is called TissuGlu and is designed to minimize fluid accumulation and other problems associated with abdominoplasty, or “tummy-tuck” surgeries.

Economic development group Pittsburgh Life Sciences Greenhouse has added three executives who will provide expertise and advice to the area’s health care start-ups.

The Pittsburgh Life Sciences Greenhouse (PLSG) replenished the coffers of three medical startups, included in $725,000 worth of direct investment. But the group isn’t close to being finished and neither are health-care startups in Pittsburgh.

Blue Belt, a 6-year-old spin-off company from Carnegie Mellon University, is making a series of tools that rely on robotic technology and computer-assisted guidance for orthopedic and neurosurgery procedures. The company says its devices can automatically adjust the depth of a cut or disable the cut entirely based on the the location of the cut, and will help physicians make better cuts.

The company in July submitted its application to the U.S. Food and Drug Administration and in August closed on $750,000 in capital. This latest funding would be a catalyst to launch the technology.

The money will start human trials on the device, called CardioARM, and complete a commercial product to be submitted for both U.S. and European approval. Cardiorobotics thinks its slender winding robot that remembers its path through the body can by used in an array of surgical procedures. But CardioARM itself could be used in up to 1 million relevant cardiac procedures a year, including ablations.